Navigation Links
Novartis Vaccines & Diagnostics to Pay More Than $72 Million to Resolve False Claims Act Allegations Concerning TOBI
Date:5/4/2010

WASHINGTON, May 4 /PRNewswire-USNewswire/ -- Novartis Vaccines & Diagnostics Inc. and Novartis Pharmaceuticals Corporation have agreed to pay $72.5 million to resolve civil False Claims Act allegations arising from the marketing of the cystic fibrosis drug TOBI, the Justice Department announced today. The settlement resolves allegations that, between Jan. 1, 2001 and July 31, 2006, Novartis and its predecessor, Chiron Corporation, caused false claims to be submitted to federal health care programs for certain off-label uses of the drug.

The Food and Drug Administration (FDA) approved TOBI, an inhaled antibiotic, for the treatment of certain cystic fibrosis patients. The United States alleges that Chiron, and then Novartis, marketed TOBI for unapproved uses, such as diseases other than cystic fibrosis, and for cystic fibrosis patients who did not meet the parameters of the FDA-approved indication and for which TOBI was not a medically accepted use. The government alleges that this conduct caused the submission of false claims to federal health care programs.

"Pharmaceutical companies must not promote their drugs for uses that have not been proven to be safe and effective," said Tony West, Assistant Attorney General for the Civil Division of the Department of Justice. "We are committed to pursuing False Claims Act violations and recovering taxpayer dollars lost to off-label marketing."

"This office is committed to safeguarding the federal health care programs against false claims caused by off-label marketing and other types of illegal conduct," said Joseph Russoniello, U.S. Attorney for the Northern District
'/>"/>

SOURCE U.S. Department of Justice
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Jury Verdict Against Novartis Pharmaceuticals For Retaliating Against Drug Sales Rep Who Took Maternity Leave
2. Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
3. Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
4. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
5. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
6. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
7. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
10. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
11. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... --  Royal Philips (NYSE: PHG ... clearance from the U.S. Food and Drug Administration to ... the U.S. VISIQ is the first Philips ... performance and simplicity into a single miniaturized solution, helping ... OB patients. This breakthrough ultrasound device can ...
(Date:7/24/2014)... , July 24, 2014  To help health ... market that could impact patient care and the ... CV Watch , "Innovations in Cardiovascular Devices."  ... with guidance and details on promising new technologies ... and understand how these options impact the supply ...
(Date:7/24/2014)... -- Second Quarter and Recent Highlights: ... Officer effective September 2, 2014 , Product revenues ... BioGlue ® revenues grew 14 percent year-over-year to ... 22 percent year-over-year to $1.1 million , HeRO ... $1.7 million , Tissue processing revenues decreased 6 ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 2Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 3New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17
... 11 In conjunction with its fourth quarter 2009 earnings release (expected ... (NYSE: CVD ) is pleased to invite you to listen ... the Internet on Thursday, January 28, 2010 at 9:00 a.m. ET. , ... and Slide Presentation, When: January 28, 2010, 9:00 ...
... 11 BD (Becton, Dickinson and Company) (NYSE: BDX ... its first fiscal quarter 2010 earnings conference call on Thursday, January ... press release detailing the quarter,s earnings earlier that morning. , The ... accessible through BD,s website at www.bd.com/investors and will be ...
Cached Medicine Technology:BD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call 2
(Date:7/24/2014)... appears to increase the risk for head and neck cancer ... with DM, but the risk of HNC in patients with ... cancer is the sixth most common type of cancer. It ... an estimated 650,000 new cancer cases and 350,000 cancer deaths ... Insurance Research Database to examine the risk of HNC in ...
(Date:7/24/2014)... This year the Walk to End Alzheimer’s ... National Life, will be held on Saturday, September 20 in ... Fun Run at 7:50 am, the untimed 5k Run at ... “The Walk to End Alzheimer’s unites the entire community in ... against this devastating disease, “stated Linda Mitchell, CEO and president ...
(Date:7/24/2014)... two or more equally positive outcomes experience paradoxical ... activity in different regions of the brain, according ... research scholar at the Princeton Neuroscience Institute at ... people rated the desirability of more than 300 ... at images of paired products with different or ...
(Date:7/24/2014)... 24, 2014 Memantine was initially developed by ... in Germany under the brand name Akatinol; it was later ... Ebixa and in the USA to Forest Labs as Namenda. ... in 2013. In the US, Forest reported Namenda sales of ... in Canada, Australia and the European region has increased the ...
(Date:7/24/2014)... scientists at Carnegie Mellon University, working with high-throughput ... Berkeley National Laboratory, have devised a computational method ... normal breast cells turn malignant and as they ... for analyzing how genes interact with each other ... published today by the online journal PLOS ...
Breaking Medicine News(10 mins):Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 2Health News:Alzheimer's Association Walk to End Alzheimer's Steps Off Saturday, September 20 in Denver 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Gene changes in breast cancer cells pinpointed with new computational method 2Health News:Gene changes in breast cancer cells pinpointed with new computational method 3
... people, mainly in developing countries, are disabled by infectious ... More than 12 million people in 88 countries are ... bite of infected sand flies. Nearly 2 million new ... the disease annually. , Researchers at the University ...
... Can a high-energy diet pill really save your job? ... manufacturers, clothing makers and other retailers are seeing a significant ... maker Zoller(R) Laboratories is reporting dramatically increased sales of ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20081216/LA52707 ) , ...
... Targeting pigments in mucus could fight deadly,bacteria in lungs ... called phenazines that stain the mucus in the lungs ... spur dangerous infections, researchers say. , The pigments may ... into structured communities, according to a Massachusetts Institute of ...
... from and odds are that they know. Or maybe not. A new ... tools to scan the human genome must pay attention to ancestry when ... ... 2008 -- Ask someone where their ancestors were from and odds ...
... Institutes of Health (NIH) has awarded nearly $3 million to ... milk impacts the health outcomes and health care cost savings ... 1500 grams. , The grant will enable researchers at ... cohort of 600 very low birth weight infants born to ...
... there,s a scientific reason why older people tend to ... A University of Alberta medical researcher, in collaboration with ... older adults to remember fewer negative events than their ... than younger people when it comes to storing memory, ...
Cached Medicine News:Health News:UIC researchers hunting drugs for devastating parasitic disease 2Health News:Sales of Energy-Boosting Diet Pills Skyrocket as the Economy Falters 2Health News:Scientists Spot Key to Cystic Fibrosis Infections 2Health News:Genome-wide Association Studies Must Account for Ancestry 2Health News:Genome-wide Association Studies Must Account for Ancestry 3Health News:Study examines how breastfeeding impacts cost of care for very low birth weight infants 2Health News:Aging brains allow negative memories to fade 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: